TCT Conference 2024 - Significant reduction in TLF and TVF and flattening of event curves after 6 months in favour of DynamX Bioadaptor.

Dr David Erlinge (Skane University Hospital, Lund, SE) joins us onsite at TCT Conference to discuss the findings from INFINITY-SWEDEHEART (NCT04562805).

INFINITY-SWEDEHEART is a prospective, multicenter, randomized registry-based clinical trial, where patients with complex lesion subsets were randomized 1:1 to receive either the DynamX Bioadaptor (Elixir Medical Corporation) or the Resolute Onyx (Medtronic) drug-eluting stent. 2400 patients in Sweden were enrolled in the trial, and were followed-up by phone at 30 days and 1 year, and by clinical and diagnostic registries at 6 months and 2 to 5 years. The primary outcome measure was target lesion failure (TLF) at one year. 

Findings showed low and non-inferior TLF rates at 12 months, and significant reduction in TLF and TVF, with a flattening of event curves after 6 months. There was a substantial clinical benefit for high-risk subgroups including acute coronary syndrome after 6 months, and consistent effect across those prespecified subgroups. 

Interview Questions:
1. What's the reasoning behind this trial?
2. What was the study design and the patient population? 
3. What were your key findings? 
4. What are the take-home messages for practice?
5. What further study is needed?

Recorded at TCT Conference in Washington, 2024.

Editor: Jordan Rance
Video Specialist: Dan Brent and Oliver Miles

Support: This is an independent interview produced by Radcliffe Cardiology.